Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.42 |
| ▸ | PGR | P06401 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393891 | 0.88 | MAPT (0.43) | NR3C1PGRALDH1A1KDM4EMEN1 | |
| SCHEMBL1828562 | 0.87 | MAPT (0.43) | NR3C1PGRALDH1A1KDM4EMEN1 | |
| SCHEMBL2405791 | 0.87 | PGR (0.48) | NR3C1PGRALDH1A1KDM4EMEN1 | |
| SCHEMBL2397433 | 0.87 | PGR (0.48) | NR3C1PGRALDH1A1KDM4EMEN1 | |
| SCHEMBL446281 | 0.86 | PGR (0.47) | NR3C1PGRALDH1A1KDM4EMEN1 | |
| SCHEMBL12236921 | 0.86 | PGR (0.47) | NR3C1PGRALDH1A1KDM4EMEN1 | |
| SCHEMBL12236738 | 0.85 | NR3C1 (0.47) | NR3C1PGR | |
| SCHEMBL2354139 | 0.85 | NR3C1 (0.42) | NR3C1PGR | |
| SCHEMBL2394270 | 0.85 | NR3C1 (0.44) | NR3C1PGRALDH1A1KDM4EMEN1 | |
| SCHEMBL1827697 | 0.85 | NR3C1 (0.47) | NR3C1PGRALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008497-B2 | 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090298826-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298826-A1 | NOVEL 1,2-DIHYDROQUINOLINE DERIVATIVE HAVING (SUBSTITUTED PHENYL OR SUBSTITUTED HETEROCYCLIC) CARBONYLOXY LOWER ALKYL GROUP AND ESTER-INTRODUCED PHENYL GROUP AS SUBSTITUENTS | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885PGR 68/4885ALDH1A1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.